15
total announcements
MOLBIO.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 17 Oct 2026
Market Cap
₹18,143 Cr
P/E (TTM)
108.9
P/E (Forward)
43.9
EPS (TTM)
₹14.46
52W Low
₹926.35
52W High
₹1,686.80
Dividend Yield
0.00%
Price / Book
15.2
Debt / Equity
34.4
Revenue (TTM)
₹1,754 Cr
Gross Margin
60.03%
Operating Margin
20.45%
Molbio Diagnostics Limited
Molbio Diagnostics Limited has seen a significant increase in trading volume, prompting the exchange to reach out to the company for information to safeguard investor interests.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30,2026, stating that the entire holding of the company is in electronic mode and no rematerialisation request was received during the period.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange regarding the re-appointment of M/s K. S. Kamalakara & Co, Cost Accountants as the Cost Auditor of the Company for FY 2026-27.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has scheduled an analyst/investor meet on September 22, 2026, to discuss general business outlook and information already in the public domain.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange about the transcript of the Earnings Call held on September 08, 2026, in relation to the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange regarding Intimation regarding change of Corporate Identification Number (CIN) of the Company.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange about the link of the recording of the earnings call for the quarter ended June 30, 2026, as per Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange about Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has published its un-audited financial results for the quarter ended June 30, 2026, in the Financial Express and Tarun Bharat newspapers.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has announced its Q1 FY27 financial results, with total income standing at ₹411.48 Cr, EBITDA at ₹103.68 Cr, and PAT at ₹52.74 Cr, showing a significant improvement from Q1 FY26.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has submitted its un-audited financial results for the quarter ended June 30, 2026, and authorized its key managerial personnel to determine the materiality of events or information.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has scheduled an Earnings Conference Call on September 8, 2026, to discuss its financial performance for the quarter ended June 30, 2026.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026, where the Board of Directors designated Mr. Darshan Raghunath Karekar as the Compliance Officer under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Molbio Diagnostics Limited
Molbio Diagnostics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.